Scarica l'app Stockscreener
26.33
0.15%
-0.04
Dopo l'orario di chiusura:
26.09
-0.24
-0.91%
Precedente Chiudi:
$26.37
Aprire:
$26.79
Volume 24 ore:
171.15K
Relative Volume:
12.63
Capitalizzazione di mercato:
$1.59B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$25.56
$27.60
Intervallo di 1 settimana:
$21.98
$27.60
Portata 52W:
$21.98
$27.60
Damora Therapeutics Inc Stock (DMRA) Company Profile
Nome
Damora Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare DMRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
26.33 | 1.59B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Damora Therapeutics Inc Borsa (DMRA) Ultime notizie
Taxes of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Statistics – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Earnings and Revenue – NASDAQ:DMRA - TradingView
Total assets of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Galecto Changes Name to Damora Therapeutics, Advances mutCALR Antibody Pipeline for Blood Disorders and Secures $535M Funding 1 - Minichart
Galecto Rebrands as Damora Therapeutics with New Ticker - TipRanks
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders - Bitget
Galecto (GLTO) Rebrands to Damora Therapeutics, Plans Nasdaq Lis - GuruFocus
Galecto rebrands as Damora Therapeutics, begins Nasdaq trading - Investing.com
Damora Therapeutics holds $535M cash to target rare blood cancers - Stock Titan
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Galecto announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Biotech brings in cancer drug veterans as it readies new antibody trial - Stock Titan
Mintz Advises Galecto, Inc. in its acquisition of Damora Therapeutics, Inc. and its concurrent $285 million private placement - Mintz
US: Galecto acquires Damora Tx and raises US$285m from Series C - Investors in Healthcare
Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally - Stocktwits
A Week Is A Long Time In Biotech, Just Ask Galecto - Citeline News & Insights
Galecto, Inc. (GLTO) Stock: Rockets After $284.9M Funding Boost and Strategic Damora Acquisition - parameter.io
Galecto Reports First Quarter 2025 Operating and Financial Results - marketscreener.com
GLTO Stock Price, News & Analysis - Stock Titan
Galecto to Participate in Upcoming Investor Conferences - marketscreener.com
Galecto Reports Third Quarter 2024 Financial Results - marketscreener.com
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - marketscreener.com
Galecto Announces Reverse Stock Split - marketscreener.com
Galecto to Present at Investor Conferences in September - marketscreener.com
Galecto Set to Join Russell Microcap® Index - marketscreener.com
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference - marketscreener.com
Galecto to Participate in SVB Securities Global Biopharma Conference - marketscreener.com
GALECTO, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - marketscreener.com
Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors - marketscreener.com
DMRA Stock Price and Chart — NASDAQ:DMRA - TradingView
Galecto Biotech AB Appoints Richard Marshall as Chief Medical Officer - marketscreener.com
Damora Therapeutics Inc Azioni (DMRA) Dati Finanziari
Non sono disponibili dati finanziari per Damora Therapeutics Inc (DMRA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Capitalizzazione:
|
Volume (24 ore):